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We performed a cost analysis of voriconazole versus caspofungin as first-line 
antifungal treatment for IA among patients with prolonged neutropenia or 
undergoing bone marrow or hematopoietic stem-cell transplantation (BMT/
HSCT) from a Chinese hospital perspective. METHODS: A decision analytic 
model with a 30-day time horizon was constructed to estimate the potential 
treatment costs of alternative interventions voriconazole versus caspofungin. 
Each pathway in the model was defined by probabilities of an event to occur and 
costs of clinical outcomes. Outcome probabilities and cost inputs (in 2014 RMB 
Yuan) were derived from published literature, clinical trials, and recommenda-
tions from expert panels. In the base case, patients who failed first-line therapy 
were assumed to either experience a single switch between study drugs or add 
on the other study drug as second-line treatment options. Base-case evaluation 
included drug management costs and additional hospitalization costs due to 
severe adverse events. RESULTS: Based on clinical trial treatment success rates 
of 52.8% (voriconazole) and 33.0% (caspofungin), and LOT= 15-day -IV + 15-day 
oral for voriconazole and 30-day IV for caspofungin, voriconazole had a lower 
total treatment cost than caspofungin (¥58,514 vs ¥67,822) despite its higher drug 
cost. Cost savings were primarily due to the higher treatment efficacy and shorter 
IV LOT associated with voriconazole. LOT and drug prices were the main cost 
drivers. The cost advantage of voriconazole persists with up to 19 days of IV treat-
ment with a proportional decrease in oral treatment to11 days. CONCLUSIONS: 
This study suggests that voriconazole is likely to be cost-saving compared to 
caspofungin in the treatment of invasive aspergillosis from the Chinese hospital 
perspective.
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OBJECTIVES: When selecting postoperative pain management (POPM) for an 
individual patient, clinicians weigh the analgesic efficacy, risk of adverse events, 
and any additional resource consumption associated with the administration 
of treatment. This analysis estimated the total cost and resource use associated 
with utilizing fentanyl iontophoretic transdermal system (ITS) versus standard 
intravenous patient-controlled analgesia (IV PCA) morphine for POPM. METHODS: 
A cost calculation model was developed to evaluate the economic value of fentanyl 
ITS compared to IV PCA morphine for a hospital performing inpatient orthopedic 
surgery. The model considered resource use and direct costs for opioid related 
adverse events (ORAEs), IV PCA medication/device errors, supplies, equipment, 
hospital staff time and drug for the management of postoperative pain. Model 
assumptions were informed by published literature, the PREMIER hospital data-
base, fentanyl ITS active-controlled trial data, and online sources. RESULTS: The 
orthopedic patient population included knee arthroplasty (Clinical Classification 
Software CCS= 152), total or partial hip replacement (CCS= 153) laminectomy with 
excision intervertebral disc (CCS= 3), or spinal fusion (CCS= 158). The duration of 
pain management modeled was 48 hours. Fentanyl ITS use reduced the per-
patient costs associated with ORAEs by $402, IV PCA medication/device errors by 
$29, and the direct costs of supplies and equipment by $98. Fentanyl ITS reduced 
RN/LPN time associated with PCA administration tasks by 38% and eliminated 
tasks performed by the pharmacy, central supply and bioengineering staff for 
a savings of $35. CONCLUSIONS: Within the hospital setting, this analysis cal-
culates fentanyl ITS may reduce the economic burden associated with ORAEs, 
pump and programming errors, labor and supply/equipment costs compared to IV 
PCA, resulting in a potential economic benefit of $579 per patient over a 48-hour 
period.
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OBJECTIVES: When making reimbursement decisions, policy-makers in China 
need to consider the economic impact of the treatment, which is determined by 
both epidemiological factors and treatment costs. In this study, we compare the 
total annual budget impact of different diseases of various treatment costs and 
prevalence rates. METHODS: We considered six diseases in our analysis: hemo-
philia B, HIV, hypertension, non-small cell lung cancer (NSCLC), tuberculosis, 
and type 2 diabetes mellitus (T2DM). These choices provided a sample of highly 
prevalent diseases (hypertension) and rare diseases (hemophilia B) as well as 
high cost (NSCLC) and low cost (type 2 diabetes) treatments. The budget impact 
was calculated by multiplying the number of patients by the cost per patient. The 
data sources for prevalence and cost were obtained using a search of previously 
published literature with the following criteria: in English, with abstract, published 
within the past ten years. All costs were converted to USD using (1 USD = 6.07 
RMB). RESULTS: China has a population of 1.3 billion, and the most common 
disease of our selection was hypertension (254 million) followed by T2DM (114 
million), HIV (1.4 million), tuberculosis (1.3 million), NSCLC (515,000), and hemo-
philia B (4,887). The annual per-patient-cost was highest for hemophilia B ($12,670) 
followed by NSCLC ($11,566), HIV ($2,242), tuberculosis ($724), hypertension ($367), 
and T2DM ($194). The budget impact was highest for hypertension ($93 billion) fol-
lowed by T2DM ($22 billion), NSCLC ($6 billion), HIV ($3 billion), tuberculosis ($900 
million), and hemophilia B ($62 million). CONCLUSIONS: When determining the 
economic impact of a treatment on a health system, payers need to consider both 
the cost of the treatment as well as the size of the patient population. Though a 
rare disease may have high cost of treatment, its budget impact is relatively small 
because of the population size.
and literature. Overall savings were calculated by subtracting the costs of compli-
cations and treatments associated with BAL adoption level for a given year from 
costs associated with current BAL adoption level and adding the incremental costs. 
Scenario analyses examined cost impacts for hospitals of various sizes, with differ-
ent BAL adoption levels and rates. RESULTS: Base case scenario analysis showed 
year 1 hospital savings of $69,846 (USD) and 5-year cumulative savings of $2.77M. 
At the pharmacy level, despite higher fluid costs, estimated savings were $9,836 
in the first year and $389,262 over 5 years. Alternate scenario analyses involving 
larger hospital size, year 5 BAL usage in greater proportions of patients and rapid/
early BAL adoption demonstrated increased cumulative savings over the 5 year 
period. CONCLUSIONS: Increased BAL usage represents an opportunity for US hos-
pitals and pharmacy departments to reduce complication-related costs associated 
with managing SIRS patients.
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OBJECTIVES: Current practice guidelines in Scotland recommend pregabalin in 
primary care if first- and second-line treatments (amitriptyline or gabapentin) 
are ineffective or poorly tolerated. Capsaicin 8% patch (QUTENZA™) is currently 
used as an add-on to pregabalin and only within a specialist setting. Scottish 
prescribers have made two suggestions to improve current care; first, using cap-
saicin 8% patch instead of pregabalin following failure of initial treatments; and 
second, administering capsaicin 8% patch within primary care. We built a model to 
evaluate the potential budget impact from implementing the suggested treatment 
practices. METHODS: The model assessed a hypothetical cohort of 100 patients 
with non-diabetic PNP, treated by a primary care physician, a pain specialist or 
both (integrated care). Two patient cohorts were modelled: pregabalin-naïve (i.e. 
previously untreated with) or pregabalin-treated. Costs were estimated for the 
base-case scenarios (secondary care use of pregabalin only for pregabalin-naïve 
and -treated patients) and new treatment pathways (replacing pregabalin with 
capsaicin 8% patch). Model input values included 150mg daily dose of prega-
balin and capsaicin 8% patches (1.45 patches/patient; 5.25 months retreatment 
time). RESULTS: In the base-case scenario for pregabalin-naïve patients, the esti-
mated cost (per 100 patients) was £82,800. The estimated costs of introducing 
capsaicin 8% patch were £92,686 (£9886 difference) in secondary care, £86,743 
(£3943) in primary care and £89,343 (£6543) in integrated care. In pregabalin-treated 
patients, the estimated base-case scenario cost was £185,200. The estimated costs 
of introducing capsaicin 8% patch were £175,486 (–£9714 difference) in secondary 
care, £169,543 (–£15,657) in primary care and £172,143 (–£13,057) in integrated 
care. CONCLUSIONS: Replacing pregabalin with capsaicin 8% patch in pregabalin-
naïve patients was associated with cost savings within primary and integrated 
care compared with secondary care. Additionally, cost savings versus pregabalin 
were observed with capsaicin 8% patch in pregabalin-treated patients within all 
three treatment pathways.
PSY21
coSt imPlicAtion of uSing lorcASErin in wEight mAnAgEmEnt Prior 
to bAriAtric SurgErY
Wang Z.1, Li X.2, Knoth R.2, Fujioka K.3
1Eisai Inc., Woodcliff Lake, NJ, USA, 2Eisai, Inc., Woodcliff Lake, NJ, USA, 3Scripps Health, San 
Diego, CA, USA
OBJECTIVES: Payers may grant coverage for bariatric surgery (BaS) for patients with 
BMI ≥ 40 or BMI 35-39.9 with ≥ 1 obesity-related comorbidities. Trial of weight loss 
(WL) medications before BaS may be beneficial to both payers and patients if some 
patients can avoid BaS. This analysis evaluated the cost impact of lorcaserin, a 
FDA- approved WL medication, in weight management prior to BaS from payer’s 
perspective. METHODS: Cost impact of lorcaserin for WL prior to BaS was assessed 
in a hypothetical US health plan of one million members over a 2-year horizon. Key 
assumptions include: 1) Average cost per BaS is $29,517; 2) Patients with BMI reduced 
to below 35 with pre-BaS WL can avoid BaS; 3) Only BaS and lorcaserin drug costs are 
included; 4) Only patients who achieve ≥ 5% weight loss at week 12 continue lorca-
serin treatment (WK-12 responders). For modeling purpose, WL data for lorcaserin 
were drawn from a subset of patients in three clinical trials (BLOSSOM, BLOOM, 
BLOOM-DM) evaluating the efficacy and safety of lorcaserin for WL. RESULTS: 42.5% 
of patients with baseline BMI≥ 40 were WK-12 responders (average BMI 42.3) and 
17.6% of them reduced BMI to below 35 at one year with lorcaserin treatment. In 
patients with baseline BMI 35-39.9 and ≥ 1 obesity-related comorbidities, 49.3% were 
WK-12 responders (average BMI 37.2), and 72.6% of them reduced BMI to below 35 
at one year with lorcaserin treatment. The cost analysis estimated cumulative sav-
ing of $1,033,407 over 2 years if patients who reduced their BMI to below 35 with 
lorcaserin can avoid BaS. CONCLUSIONS: From payer’s perspective, using lorcaserin 
for WL prior to BaS may lead to significant cost saving over a 2-year horizon. Real 
world, long-term evidence is needed for further evaluation of the role of lorcaserin 
for weight management in patients considering BaS.
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OBJECTIVES: Published real-world studies suggested voriconazole (Vfend) may 
provide reduced length-of-stay, intravenous (IV) length-of-therapy (LOT), and 
costs compared to caspofungin (Cancidas) in invasive aspergillosis (IA) patients. 
